Mia Hu, formerly investment associate at Boehringer Ingelheim Venture Fund, has been named investment director at the unit.

Mia Hu headshot
Mia Hu (photo courtesy of LinkedIn)

Germany-headquartered pharmaceutical firm Boehringer Ingelheim (BI) has promoted Mia Hu to investment director for its BI Venture Fund.

Hu joined BI Venture Fund in 2021 as a Hong Kong-based investment associate director, working on healthcare investment and incubation. She sits on the board of Nuevocor, the Singaporean gene therapy developer that received funding from the corporate venturing fund in November 2022.

Formed in 2010, BI Venture Fund has 39 active portfolio companies and made six fund investments. Out of its 51 direct investments, 10 were acquired – half of which by its parent firm and the others by healthcare firms.

Most of BI Venture Fund’s portfolio companies are based in North America and Europe, but it has also backed two Chinese companies: vaccine developer Delonix Bioworks and RiboX Therapeutics, which is working on RNA therapies.

Before joining BI, Hu was senior vice president at China Resources Capital Management, part of real estate conglomerate China Resources.

In addition to her role at BI, Hu also serves on the HKSTP X BIVF Co-incubation Program Steering Committee, part of the government-sponsored Hong Kong Science and Technology Parks Corporation.

Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.